In a secondary analysis of the ASPREE trial in 19,114 community-dwelling adults aged ≥70 (≥65 for US minority groups), daily 100 mg aspirin did not reduce loss of healthspan versus placebo over a median 4.7 years (82.1 vs 82.7 events/1000 person-years; HR 0.98, 95% CI 0.92–1.05).
Secondary analysisn = 19,114
Zheng et al. Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study